Xavier Sáez-Llorens

  1. Sáez-Llorens X, Mendez J, Chorres C. Analysis of mortality and morbidity rates of very-low weight birth. Bol Soc Pediatr Panama 1984; 13:5-19.
  2. Sáez-Llorens X, Baez C, Urrutia J.  Neonatal hyperammonemic Coma.  Bol Soc Pediatr Panama 1984; 13:31-39.
  3. Mendez J, Sáez-Llorens X, Espino R.  Diabetes mellitus and pregnancy. Maternal Aspects.  Rev Med CSS 1985; 17:84-87.
  4. Sáez-LLorens X, Mendez J, Espino R.  Diabetes mellitus and pregnancy. Neonatal Aspects.  Rev Med CSS 1985; 17:88-91.
  5. Sáez-Llorens X, Baez C, Dillman L, Paredes E.  Appendicitis in children.  Bol Soc Pediatr Panama 1985; 14:35-45.
  6. Cowan J, Sáez-Llorens X.  Vascular rings in infants. Rev Med CSS 1985; 17:80-83.
  7. Sáez-Llorens X.  Congenital syphilis.  Bol Prog Mat- Infantil, November 1985.
  8.  Sáez-LLorens X, Baez C, De La Lastra E.  Meningitis caused by Haemophilus influenzae type b.   Rev Med CSS 1986; 18:1-9.
  9. Baez C, Sáez-Llorens X, Ruiz F.  General aspects of acute infantile bacterial diarrhea.  Bol Soc Pediatr Panama. 1986; 15:12-18.
  10. Rivas De La Lastra E, Sáez-Llorens X, Baez de Ulloa C. Clinical-bacteriologic correlation of acute diarrhea in children.  Rev Med Panama 1986; 11:193-198.
  11. Rivas De La Lastra E, Sáez-Llorens X, Baez de Ulloa C. Symptoms and signs observed in children with acute diarrhea suggest the etiologic agent. Rev Med Panama 1987; 12:52-55.
  12. Rivas De La Lastra E, Baez de Ulloa C, Sáez-Llorens X. Normal values of cerebrospinal fluid in Pediatrics.Rev Med Panama 1988; 13:126-128.
  13. Sáez-Llorens X, Umana M, Odio C, Lohr J.  Bacterial contamination rates for non-clean catch and clean catch midstream urine collections in uncircumcised boys. J Pediatr 1989; 114:93-95.
  14. Sáez-Llorens X, Guzman LM, Shelton S, Nelson JD, Kupersztoch Y. Simultaneous detection of Escherichia coli heat-stable and heat-labile enterotoxin genes with a  single RNA probe.  J Clin Microbiol 1989; 27:1684-1688.
  15. Sáez-Llorens X, Odio C, Umana C, Morales M.  Spiramycin vs placebo for treatment of acute diarrhea caused by Cryptosporidium.  Pediatr Infect Dis J 1989; 8:136-140.
  16. Sáez-Llorens X, Umana M, Odio C, McCracken GH, Jr., Nelson  JD.  Brain abscess in children.  Pediatr Infect Dis J. 1989; 8:449-458.
  17. Sáez-Llorens X. Spiramycin for treatment of Cryptosporidium enteritis.  J Infect Dis 1989; 160:342.
  18. Mertsola J, Ramilo O, Sáez-Llorens X, Hanson MS, McCracken GH, Jr., Hansen EJ.  Specific detection of Haemophilus influenzae type b lipoligosaccharide by a polymyxin B- monoclonal antibody assay. J Immunol Methods 1989; 122:219.
  19. Mustafa MM, Mertsola J, Ramilo O, Sáez-Llorens X, Risser  RC, McCracken GH, Jr. Increased endotoxin and interleukin-1 beta concentrations in cerebrospinal fluid of infants with coliform meningitis and ventriculitis              associated with intraventricular gentamicin therapy. J Infect Dis 1989; 160:891-895.
  20. Mustafa MM, Sáez-Llorens X, McCracken GH, Jr., Nelson JD. Acute Hematogenous Pelvic osteomyelitis in infants and   children.  Pediatr Infect Dis J 1990; 9:416-421.
  21. Sáez-Llorens X, Mustafa MM, Ramilo O, Fink C, Beutler B, Nelson JD.  Tumor necrosis factor and interleukin-1 beta in children with suppurative arthritis.  Am J Dis Child 1990; 144:353-356.
  22. Ramilo O, Mustafa MM, Porter J, Sáez-Llorens X, Mertsola J Olsen KD, Luby JP, Beutler B, McCracken GH, Jr.  Detection of interleukin-1 beta but not tumor necrosis factor alpha  in CSF of children with aseptic meningitis.  Am J Dis              Child 1990; 144:349-352.
  23. Mertsola J, Munford B, Ramilo O, Sáez-Llorens X, McCracken GH, Jr., Hansen EJ.  Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay. J Clin Microbiol 1990; 28:2700-2706.
  24. Mustafa MM, Ramilo O, Sáez-Llorens X, Magness R, McCracken GH, Jr.  Prostaglandins, IL-1, and TNF in bacterial meningitis. Clinical and laboratory correlations in placebo and dexamethasone treated patients.  Am J Dis Child 1990; 144:883-887.
  25. Sáez-Llorens X, Ramilo O, Mustafa MM, Mertsola J, De Alba  C, Hansen EJ, McCracken GH, Jr.  Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.  Antimicrob Ag Chemother 1990; 34:837-843.
  26. Mustafa MM, Ramilo O, Sáez-Llorens X, Magness R, McCracken GH, Jr.  Prostaglandins E2 and I2, IL-1 beta, and TNF in  CSF of infants and children with bacterial meningitis.  Pediatr Infect Dis J 1989; 8:921-922.
  27. Mustafa MM, Ramilo O, Sáez-Llorens X, Mertsola J, Hansen EJ, McCracken GH, Jr.  Role of tumor necrosis factor alpha (cachectin) in experimental and clinical bacterial meningitis.  Pediatr Infect Dis J 1989; 8:907-908.
  28. Sáez-Llorens X, Ramilo O, Mustafa MM, Mertsola J, Hansen EJ, McCracken GH, Jr.  Modulation of meningeal  inflammation by treatment with Pentoxifylline.  Pediatr  Infect Dis J 1989; 8:922-923.
  29. Mertsola J, Ramilo O, Mustafa MM, Sáez-Llorens X, Hansen EJ, McCracken GH, Jr.  Release of endotoxin after antibiotic treatment of Gram-negative bacterial                    meningitis.  Pediatr Infect Dis J 1989; 8:904-906 .
  30. Ramilo O, Mustafa MM, Sáez-Llorens X, Mertsola J, Ohkawara S, Yoshinaga M, Hansen EJ, McCracken GH, Jr. Role of IL-1 in meningeal inflammation.  Pediatr Infect Dis J 1989; 8:909-910.
  31. Sáez-Llorens X, Ramilo O, Mustafa MM, Mertsola J, McCracken GH, Jr.  Molecular pathophysiology of bacterial meningitis.  Current concepts and therapeutic  implications.  J Pediatr 1990; 116:671-684.
  32. Sáez-Llorens X, Shelton S, Kuzmiess H, Sia Li B, Nelson JD. Pharmacokinetics of cefprozil in children. Antimicrob Agents Chemother 1990; 34:2152-2155.
  33. Ramilo O, Sáez-Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, Yoshinaga M, Ohkawara S, Nariuchi H, McCracken GH, Jr.  TNF alpha/Cachectin and Interleukin-1 beta initiate meningeal inflammation.  J Exp Med 1990;               172:497-507.
  34. Sáez-Llorens X, McCracken GH, Jr. Bacterial meningitis in neonates and children.  Infect Dis Clin North America 1990; 4:623-644.
  35. Sáez-Llorens X and McCracken GH, Jr.  Mediators of Meningitis: Therapeutic Implications.  Hosp Prac 1991; 26:68-77.
  36. Jafari HS, Sáez-Llorens X, Ramilo O, Shelton SL, McCracken GH, Jr.  Pharmacokinetics and Antibacterial efficacy of Cefpirome (HR 810) in Experimental Escherichia coli and Haemophilus influenzae type b Meningitis.  Antimicrob Agents Chemother 1991; 35:150.
  37. Sáez-Llorens X, Jafari HS, Olsen KD, Hansen EJ, McCracken GH, Jr.  Induction of Suppurative Arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor alpha and interleukin-1 beta.  J Infect Dis 1991; 163:1267-1272.
  38. Odio CM, Faingezicht I, Paris M, Nassar M, Rogers J, Sáez-Llorens X, Olsen KD, McCracken GH, Jr.  The beneficial effects of early dexamethasone administration on CSF pressure, meningeal inflammation and clinical outcome in infants and children with bacterial meningitis. New Engl J Med 1991; 324:1525 1531.
  39. Jafari HS, Sáez-Llorens X, Grimprel E, Craig Argyle J, Olsen KD, McCracken GH, Jr.  CSF characteristics and histophatologic features of central nervous system Candida albicans infection in an experimental model. J Infect Dis

1991; 164:389-395.

  1. Sáez-Llorens X, Jafari HS, Severien C, Parras F, Olsen KD,  Hansen EJ, Singer II, McCracken GH, Jr.  Enhanced   attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal                 antibodies and dexamethasone in experimental Haemophilus meningitis.  J Clin Invest 1991; 88:2003-2011.
  2. Mertsola J, Cope LD, Sáez-Llorens X, Ramilo O, Kennedy W,          McCracken GH, Hansen EJ.  In vivo and in vitro expression of Haemophilus influenzae type b lipooligosaccharide epitopes.  J Infect Dis 1991; 164:555-563.
  3. Mertsola J, Kennedy W, Waagner D, Sáez-Llorens X, Olsen K,Hansen EJ, McCracken GH.  CSF endotoxin concentrations correlate with clinical severity and neurological outcome of Haemophilus influenzae type b meningitis.  Amer J Dis Child 1991; 145:1099-1103.
  4. Sáez-Llorens X.  Management of bacterial meningitis: Antibiotics and steroids.  Anot Pediatr No.37, Mayo 1991.
  5. Sáez-Llorens X.  Guidelines for clinical evaluation of  antimicrobial agents. Bol Soc Panam Pediatr 1991; 20:85.
  6. Sáez-Llorens X.  Current concepts on sepsis, meningitis and pneumonia in neonates. Rev Hosp Niño 1991; 10:103.
  7. Sáez-Llorens X.  Current management of acute pharyngitis. Bol Soc Pan Pediatr 1992; 21:19-32.
  8. Gonzalez A, Shakalli M, Sáez-Llorens X.  Meningoencephalitis caused by Herpes simplex in a neonate. First case described  in the Hospital del Niño.  Rev Hosp Niño 1992; 11:19-23.
  9. Castaño E, Moreno B, Sáez-Llorens X.  Infectious complications in neutropenic leukemic children with fever. A retrospective review. Rev Hosp Niño 1992; 11:31-35.
  10. Sáez-Llorens X.  Possibility of being infected with the AIDS virus in our hospital.  Rev Hosp Niño 1992; 11:45.
  11. Castaño E, Sáez-Llorens X.  Management and antimicrobial therapy of human and animal bites in children.  Rev Hosp Niño 1992; 11:64.
  12. Sáez-LLorens X. Likelihood of an immunodeficiency in children with recurrent infections. Bol Soc Panam Pediatr 1992; 21:119-124.
  13. Sáez-Llorens X.  Infectious mononucleosis: current concepts.  Rev Hosp Niño 1992; 11:86.
  14. Castao E, García R, Villalaz F,. et al.  Open, randomized designed study to compare the safety and efficacy of  cefepime versus cefotaxime for treatment of bacterial  meningitis in children (a preliminary report). Bol Soc Panam Pediatr 1993;22:17-23.
  15. Sáez-Llorens X.  Election of antibiotics for acute otitis media: be aware when interpreting clinical trials. Rev Hosp. Niño 1993; 12:44-45.
  16. Sáez-Llorens X and Lagrutta F.  The acute host phase reaction during bacterial infections in children.  Pediatr  Infect Dis J 1993; 12:83-87.
  17. Sáez-Llorens X and McCracken GH, Jr.  Initial management of bacterial meningitis: steroids and antibiotics.  Res Staff Phys 1993; 39:25-29.
  18. Sáez-Llorens X.  Pathophysiology of bacterial meningitis and its clinical-therapeutic implications.  Rev Enf Infecc  Pediatr 1993; 7:92-100.
  19. Sáez-Llorens X and McCracken GH, Jr.  Sepsis syndrome and septic shock in children: current concepts on terminology, pathophysiology and management. J Pediatr 1993; 123:497-508.
  20. Sáez-LLorens X, Vega S, Quintero B. Antimicrobial resistance of common pediatric community-acquired pathogens. Rev. Hosp. Niño 1993; 12:16-19.
  21. Ríos CD, Sáez-LLorens X, Suman O. Nosocomial infections in the Hospital del Niño. Rev Hosp Niño 1993; 12:61-64.
  22. Sáez-LLorens X. AIDS and the origin of species. Rev Hosp

Niño 1993; 12:106-107.

  1. Jafari HS, Sáez-LLorens X, Paris M, et al. Dexamethasone attenuation of cytokine-mediated articular cartilage degradation in experimental lapine Haemophilus arthritis. J Infect Dis 1993; 168:1186-93.
  2. Jafari HS, Sáez-LLorens X, Severien C, et al. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis. Antimicrob Ag Chemother 1994; 38:83-89.
  3. Sáez-LLorens X, Velarde J, Cantón C. Pediatric osteomyelitis in a developing country. Clin Infect Dis 1994; 19:323-324.
  4. Moreno MT, Vargas S, Poveda R, Sáez-LLorens X. Neonatal  sepsis and meningitis in a latinamerican country. Pediatr  Infect Dis J 1994; 13:516-520.
  5. Sáez-LLorens X. Pathogenesis of Acute Otitis Media. Pediatr Infect Dis J 1994; 13:1305-8.
  6. Sáez-LLorens X. Bacterial meningitis in Pediatrics. Rev Med Científica 1994; 9:49-59.
  7. Castaño E, Villera K, Bambú M, Sáez-Llorens X. Usefulness of C-reactive protein for the management of bacterial meningitis in infants and children.  Bol Soc Panameña Pediatr 1994;23:3-8.
  8. Sáez-Llorens X, Cantón C, Hernández D, Muñoz A. Osteoarticular infections in children: a retrospective review. Bol Soc Panameña Pediatr 1994; 23:9-16.
  9. Castaño E, Ortega C, Vallarino D, Sáez-Llorens X. Comparación de 4 antibióticos en el tratamiento de niños con faringitis estreptocóccica. Bol Soc Panam Pediatr 1994; 23:63-7.
  10. Baez C, Sáez-Llorens X, Sanjur MB, Corro M. Presentación atípica de una panencefalitis subaguda esclerosante. Bol Soc Panam Pediatr 1994; 23:83-93.
  11. Sáez-Llorens X. Meningitis Aséptica Viral. Rev Med Científica 1994; 9:61-65.
  12. Sáez-Llorens X, Espino RT, Moreno MT, Vargas S. Sepsis neonatal: Diferencias en la epidemiología y microbiología de dos unidades materno-infantiles metropolitanas (1975-1992). Bol Soc Panam Pediatr 1995; 24:26-33.
  13. Sáez-Llorens X, Vargas S, Guerra F, Coronado L. Application of new sepsis definitions to evaluate outcome of pediatric patients with severe systemic infections. Pediatr Infect Dis J 1995; 14:557-561.
  14. Sáez-Llorens X, Castaño E, García R, et al. A prospective randomized comparison of cefepime and cefotaxime for the treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995; 39:937-40.
  15. Sáez-Llorens X, Ah Chu MS, Castaño E, et al. Intrapartum ceftriaxone decreases rates of bacterial colonization and early-onset sepsis in neonates. Clin Infect Dis 1995; 21:876-880.
  16. Vargas S, Guerra F, Coronado L, Sáez-Llorens X. Sepsis en la Unidad de Terapia Intensiva: Revisión de 12 años (1981-1992. Rev Hosp Niño (Panamá) 1995; 14:7-10.
  17. Guerra F, Ríos C, Sáez-Llorens X. Manejo expectante de la Meningitis Aséptica. Valor de una segunda punción lumbar. Rev Hosp Niño (Panamá) 1995; 14:15-17.
  18. Suman O, Morós D, Villarreal G, Sáez-Llorens X. Esterilidad de las batas usadas para la manipulación de pacientes criticamente enfermos. Rev Hosp Niño (Panamá) 1995; 14:22-25.
  19. Sáez-Llorens X, Ah Chu MS, Castaño E, et al. Ceftriaxona administrada intrapartum: Impacto sobre la colonización y la sepsis temprana neonatal. Bol Soc Panam Pediatr 1996; 25:5-14.
  20. Sáez-llorens X, Moreno MT, Cortés R, et al. Seroprevalencia de las hepatitis A, B y C en embarazadas panameñas. Bol Soc  Panam Pediatr 1996; 25:26-33.
  21. Sáez-Llorens X. Terapia adjunta de la meningitis bacteriana. Rev Enferm Infecc Pediatr 1996; Dic (Suppl):30-32.
  22. Sáez-Llorens X, Castaño E. Fisiopatogenia de la meningitis bacteriana. Rev Enferm Infecc Pediatr 1996; Dic (Suppl):15-16.
  23. Sáez-Llorens X. Guías para el análisis crítico de la literatura médica. Pediatr Panama 1997; 26:34-36.
  24. Sáez-Llorens X. Claves para diferenciar infecciones virales de infecciones bacterianas. Pediatr Panama 1997; 26:56-61.
  25. Sáez-Llorens X. Diferenciación entre infecciones virales y bacterianas: Necesidad urgente para evitar la resistencia antimicrobiana. Rev Panam Infect 1997; 1:20-25.
  26. Suman O, Morós D, Sáez-Llorens, Ríos C. Utilidad de la PPD en niños previamente vacunados con BCG. Rev Hosp Niño 1997; 15:13-16.
  27. Sáez-Llorens X, Quiróz E, Ledezma C, Bravo F. Un caso atípico de rubeola durante la epidemia actual de dengue. Rev Hosp Niño 1997; 15:42-44.
  28. Sáez-Llorens X. Los diferentes tipos de médicos y la aversión a la discusión y a la crítica. Rev Hosp Niño 1997; 15:140-141.
  29. Sáez-Llorens X. Circuncisión: ¿Maltrato Infantil? Rev Hosp Niño 1997; 15:151-152.
  30. Castrejón MM, Sáez-Llorens X. Profilaxis antimicrobiana: ¿Qué es?, ¿A quiénes?, ¿Cómo?, ¿Por cuánto tiempo?. Rev Hosp Niño 1997; 15:124-130.
  31. Moreno MT, Iovane MT, Velásquez D, Sáez-Llorens X. Utilidad de las tiras reactivas de urianálisis para el diagnóstico precoz de meningitis en niños. Pediatr Panama 1997; 26:118-122.
  32. Sáez-Llorens X et al. Phase I/II, multi-dose escalation prophylaxis study of a humanized RSV monoclonal antibody in healthy children with history of bronchopulmonary dysplasia or prematurity. Pediatr Infect Dis J 1998; 17:787-791.
  33. Sáez-Llorens X, Sánchez P, Ramilo O, Connor E, and the MI-CP009 Study Group. Phase I/II, double-blind, placebo-controlled, multi-dose escalation trial of a humanized RSV monoclonal antibody in children hospitalized with bronchiolitis. Pediar Infect Dis J 2004;(In press).
  34. Sáez-Llorens X, O´Ryan M. Cefepime in the empiric treatment of meningitis in children. Pediatr Infect Dis J 2001; 20:356.
  35. Sáez-Llorens X, Ramilo O. Protease Inhibitors in HIV-infected children: a first glance. Pediatr Infect Dis J 1998; 17:728-738.
  36. Sáez-Llorens X, McCracken GH, Jr. Antimicrobial and anti-inflammatory therapy of bacterial meningitis. Infect Dis Clin North America 1999; 13:619-636.
  37. Saez-Llorens X. The alarming increase of microbial resistance to antibiotics: our guilty must be solved. Rev Med Panama 1997; 22:70-71.
  38. Sáez-Llorens X. Las Inmunizaciones en Pediatría. Pediatr Panama 1998; 27:46-49.
  39. Sáez-Llorens X. Cómo debemos formar a nuestros futuros pediatras. Pediatr Panama 1998; 27:57-58.
  40. Sáez-Llorens X, Castaño E, Castrejón MM, et al. Importance of Chlamydia pneumoniae and Mycoplasma pneumoniae in children with community-acquired pneumonia. Rev Med Panama 1998; 23:27-33.
  41. Sáez-Llorens X, Castrejón MM, Castaño E, et al. Impact of an antibiotic-restriction policy on expenditures, bacterial susceptibilities, and outcome: A lesson from a pediatric developing institution. Pediatr Infect Dis J 2000; 19:200-206.
  42. Sáez-Llorens X, et al. Abacavir in the treatment of HIV-infected children. Pediatrics 2001;107:E4.
  43. Nieto JA, Castrejón MM, Sáez-Llorens X. Características de la meningitis enteroviral en niños: ¿es posible predecir su etiología? Rev Med Científica 2001; 14:8-11.
  44. Sáez-Llorens X. Novedades en SIDA Pediátrico. Rev Med Científica UP 1999; 13:35-36.
  45. Castrejón MM, Castaño E, Suman O, et al. Impacto de una política de restricción de antibióticos en el gasto hospitalario y en la susceptibilidad antimicrobiana. Pediatr Panama 1999; 28:7-18.
  46. Sáez-Llorens X, Suman O, Morós D. Penicilina intramuscular: ¿Antibiótico o tranquilizante? ¿Necesidad o costumbre? Pediatr Panama 2000; 29:11-15.
  47. Rivas de la Lastra E, Kant R, Vieto E, Sáez-Llorens X. Normas sobre prevención perinatal del SIDA. Pediatr Panamá 2001; 30:37-39.
  48. Sáez-Llorens X, et al. Quinolone treatment for pediatric bacterial meningitis. Pediatr Infect Dis J 2002; 21:14-22.
  49. Sáez-Llorens X. Starry, Starry night. Pediatr Infect Dis J 2002; 21:254.
  50. Sáez-Llorens X. Impact of invasive pneumococcal infection in children. An Esp Pediatr 2002; 57:391-393.
  51. McCoig C, Castrejón MM, Castaño E, et al. Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. J Pediatr 2002; 141:36-44-.
  52. Sáez-LLorens X, Suman O, de Morós D, Pilar Rubio M. Complicaciones y costos asociados a la Varicela en niños inmunocompetentes. Rev Panam Salud Pública 2002; 12:111-116.
  53. Sáez-Llorens X, McCracken GH. Bacterial meningitis in children. Lancet 2003; 361:2139-2148.
  54. Sáez-Llorens X, et al. Lopinavir/ritonavir in pediatric HIV treatment. Pediatr Infect Dis J 2003; 22:216-224.
  55. Castrejón MM, et al. Terapia de la otitis media: un reto terapéutico. Pediatr Panamá 2002; 31:75-80.
  56. Moreno MT, et al. Impacto neonatal de la atención de embarazadas de distintas clases sociales. Pediatrica Panamá 2002; 31:5-10.
  57. Sáez-Llorens X, et al. Tosferina: la epidemia negada. Pediatr Panamá 2002; 31:30-35.
  58. Sáez-Llorens X. Brain abscess in children. Semin Pediatr Infect Dis 2003; 14:108-114.
  59. Sáez-Llorens X, Suman O, Morós D. Varicela: Una infección costosa y no tan benigna. Rev Hosp. Niño Panama 2003; 19:17.
  60. Nieto J, Pangua M, Fernández S, et al. Características de la invaginación intestinal en niños panameños. Rev Hosp. Niño Panama 2003; 19:10.
  61. Suman O, Castillo I, Racine J, Sáez-Llorens X. Seroprevalencia de hepatitis A y varicela en Panamá. Rev Hosp. Niño Panama 2003; 19:23.
  62. Estripeaut D, Sáez-Llorens X. Encefalitis: un reto diagnóstico. Rev Hosp Niño Panama 2003 ; 19 :24.
  63. Sáez-Llorens X. Exclusión de niños de la escuela por infección. Rev Hosp. Niño Panamá 2003; 19:46.
  64. Arguedas A, Sher L, López E, Sáez-Llorens X, et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J 2003; 22:949-956.
  65. Castrejón MM, Nieto J, Suman O, et al. ¿Conoce usted la etiología de la Otitis Media Aguda en nuestros niños panameños? Pediatr Panamá 2003; 32:7-12.
  66. Suman O, Sáez-Llorens X. Infecciones nosocomiales en un hospital pediátrico de tercer nivel. Pediatr Panamá 2003; 32:13-19.
  67. Castaño E, Cisternas O, Vaca I, Sáez-Llorens X. Patrones de resistencia de cepas de Candida aisladas en pacientes internados en el Hospital del Niño de Panamá. Pediatr Panamá 2003; 32:20-23.
  68. Sáez-Llorens X, Nieto-Guevara J. Intussusception and rotavirus vaccines: what is the background risk? Pediatr Infect Dis J 2004; 23:363-365.
  69. Sáez-Llorens X. Can we eliminate the need for vaccines if natural approaches such as better hygiene and sanitation, breastfeeding and botanic remedies are enforced? Vaccines: Children and Practice 2003; 6:48.
  70. McCoig C, Castrejón MM, Saavedra-Lozano J, et al. Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2004; 23:114-118.
  71. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple dose administration. Antimicrob Agents Chemother 2004; 48:2166-72.
  72. Troitiño M, Norte G, Sáez-Llorens X. Alimentando nuestras bacterias intestinales amigas. Prebióticos y prebióticos. Rev Hosp. Niño Panama 2004; 20:22-28.
  73. Sáez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalizad with respiratory syncytial virus infection. Pediatr Infect Dis J 2004; 23:707-12.
  74. Castrejón MM, Suman O, Castaño E, Nieto J, Morós D, Sáez-Llorens X. Impacto de la terapia antiretroviral en la calidad de vida de los niños panameños con SIDA. Pediatr Panama 2003; 32:49-54.
  75. Troitiño M, Norte G, Sáez-Llorens X. Carácterísticas epidemiológicas de la enfermedad de Kawasaki en los niños panameños. Pediatr Panama 2003; 32:73-77.
  76. Nieto J, Esquivel R, Chong D, Rodríguez J, Sáez-Llorens X. Levofloxacina en la neumonía adquirida de la comunidad en el paciente pediátrico: elección o alternativa terapéutica. Pediatr Panama 2004; 33:78-83.
  77. Esquivel R, Nieto J, Policart R, Sáez-Llorens X. Factores clínicos y epidemiológicos asociados al desarroloo de invaginación intestinal en niños. Pediatrica Panama 2004; 33:33
  78. Forero I, Norte G, Moreno MT, Cisternas O, Vaca I, Sáez-Llorens X. Velocidad de crecimiento del estafilococo coagulasa-negativa en hemocultivos y su relación a patogenicidad neonatal de importancia clínica. Rev Hosp. Niño Panama 2005; 21:7-13.
  79. Troitiño M, Forero I, Norte G, Nieto J, Sáez-Llorens X. Factores de riesgo para secuelas auditivas en meningitis bacteriana. Rev Hosp. Niño Panama 2005; 21:29-35.
  80. Sáez-Llorens X, Rodríguez A, Arguedas A, Hamed KA, Yang J, Pierce P, Echols R. Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children.
    Pediatr Infect Dis J 2005; 24:293-300.
  81. Pichichero ME, Arguedas A, Dagan R, Sher L, Sáez-Llorens X, Hamed K, Echols R. Safety and Efficacy of Gatifloxacin Therapy for Children with Recurrent Acute Otitis Media (AOM) and/or AOM Treatment Failure.
    Clin Infect Dis 2005; 41:470-8.
  82. Sáez-Llorens X, Castrejón MM, Castaño E, et al. Clinical and virological correlation between the cerebrospinal fluid and blood of HIV-infected children. Rev Med Panama 2001; 26:13.
  83. Echols R, Hamed K, Arguedas A, Dagan R, Sher L, Sáez-Llorens X, Pichichero ME. Gatifloxacin therapy for children: turn on the light. Clin Infect Dis 2005; 41:1824.
  84. Ruiz-Palacios GM, Pérez-Schael I, Velásquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11.
  85. Estripeaut D, Aramburú MG, Sáez-Llorens X, Thompson HA, Dasch GA, Paddock CD, Zaki S, Eremeeva ME. Rocky Mountain spotted fever, Panama. Emerg Infect Dis 2007; 13:1763-5.

 

  1. Sáez-Llorens X, McCracken GH Jr. Glycerol and bacterial meningitis. Clin Infect Dis 2007; 45:1287-9.
  2. Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 2007; 26:868-78.
  3. Rubino CM, Ambrose P, Cirincione B, Arguedas A, Sher L, Lopez E, Sáez-Llorens X, Grasela DM. Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagn Microbiol Infect Dis 2007; 59:67-74.
  4. Estripeaut D, Moreno Y, Ahumada Ruiz S, Martínez A, Racine JD, Sáez-Llorens X. Seroprevalence of cytomegalovirus infection in puerperal women and its impact on their newborns. An Pediatr (Barc) 2007; 66:135-9.
  5. Larrú Martínez B, Quiroz E, Bellón JM, Esquivel R, Nieto Guevara J, Sáez-Llorens X. Dengue infection in children and adolescents in Panama. An Pediatr (Barc) 2006; 64:517-22.
  6. Sáez-Llorens X. Persistence of dengue in the tropics. An Pediatr (Barc) 2006; 64:515-6.
  7. Rueda K, Moreno MT, Espinosa M, Sáez-Llorens X. Impact of routine fluconazole prophylaxis for premature infants with birth weights of less than 1250 grams in a developing country. Pediatr Infect Dis J 2010 Nov; 29(11):1050-2

 

  1. Sáez-Llorens X. Impact of vaccination against rotavirus on hospitalization for acute severe gastroenteritis. Rev Panam Salud Publica 2009 Apr; 25(4):375-6;

 

  1. Sáez-Llorens X, Yogev R, Arguedas A, Rodriguez A, Spigarelli MG, De León Castrejón T, Bomgaars L, Roberts M, Abrams B, Zhou W, Looby M, Kaiser G, Hamed K. Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. Antimicrob Agents Chemother 2009 May; 53(5):1912-20.

 

  1. Sáez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, Ruiz G, Raghavan J, Bradshaw SK, Kartsonis NA, Sun P, Strohmaier KM, Fallon M, Bi S, Stone JA, Chow JW. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009 Mar; 53(3):869-75

 

  1. Linhares AC, Velázquez FR, Pérez-Schael I, Sáez-Llorens X, Abate H, Espinoza F, López P, Macías-Parra M, Ortega-Barría E, Rivera-Medina DM, Rivera L, Pavía-Ruz N, Nuñez E, Damaso S, Ruiz-Palacios GM, De Vos B, O’Ryan M, Gillard P, Bouckenooghe A; Human Rotavirus Vaccine Study Group. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008 Apr 5;371(9619):1181-9

 

  1. Constenla D, Ortega-Barría E, Rheingans RD, Antil L, Sáez-Llorens X. Economic impact of rotavirus vaccination in Panama. An Pediatr (Barc) 2008 Feb; 68(2):128-35

 

  1. Saez-Llorens X, Violari A, Ndiweni D, Yogev R, Cashat M, Wiznia A, Chittick G, Harris J, Hinkle J, Blum MR, Adda N, Rousseau F; FTC-203 Study Team. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects. Pediatrics 2008 Apr; 121(4):e827-35
  2. Luciani K, Luciani K, Nieto-Guevara J, Sáez-Llorens X, de Summan O, Morales D, Cisternas O, Bolaños R, Ramos R, Estripeaut D. Methicillin-resistant Staphylococcus aureus disease in Panama. An Pediatr (Barc). 2011 Mar 30.

 

  1. Tregnaghi MW, Abate HJ, Valencia A, Lopez P, Da Silveira TR, Rivera L, Rivera Medina DM, Saez-Llorens X, Gonzalez Ayala SE, De León T, Van Doorn LJ, Pilar Rubio MD, Suryakiran PV, Casellas JM, Ortega-Barria E, Smolenov IV, Han HH; the Rota-024 Study Group. Human Rotavirus Vaccine Is Highly Efficacious When Coadministered With Routine Expanded Program of Immunization Vaccines Including Oral Poliovirus Vaccine in Latin America. Pediatr Infect Dis J. 2011 Jun;30(6):e103-e108.

 

  1. Sáez-Llorens X, Velázquez FR, Lopez P, Espinoza F, Linhares AC, Abate H, Nuñez E, Venegas G, Vergara R, Jimenez AL, Rivera M, Aranza C, Richardson V, Macias-Parra M, Ruiz Palacios G, Rivera L, Ortega-Barria E, Cervantes Y, Rüttimann R, Rubio P, Acosta CJ, Newbern C, Verstraeten T, Breuer T. A multi-country study of intussusception in children under 2 years of age in Latin America: analysis of prospective surveillance data. BMC Gastroenterol. 2013 May 27;13(1):95

 

  1. Rüttimann RW, Gentile A, Parra MM, Saez-Llorens X, Safadi MA, Santolaya ME. A consensus statement: meningococcal disease among infants, children and adolescents in latin america. Pediatr Infect Dis J. 2014 Mar;33(3):284-90.

 

  1. Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP. Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness. Pediatr Infect Dis J. 2013 Dec 18.

 

  1. Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, Burgner D, Bainto E, Pierce D, Tyree M, Cayan D; Kawasaki Disease Global Climate Consortium. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013 Sep 18;8(9):e74529.

 

  1. Sáfadi MA, de los Monteros LE, López EL, Sàez-Llorens X, Lemos AP, Moreno-Espinosa S, Ayala SG, Torres JP, de Moraes JC, Vázquez JA. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Expert Rev Vaccines. 2013 Aug;12(8):903-15.

 

  1. Sáez-Llorens X, Guevara JN. Brain Abscess. Handb Clin Neurol. 2013;112:1127-34.

 

  1. Tregnaghi MW, Sáez-Llorens X, López P, et al. Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial. PLoS Med. 2014 Jun 3;11(6):e1001657.

 

  1. Ramilo O, Lagos R, Sáez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 2014; 33:703

 

 

  1. Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2015 Dec 21.

 

  1. Rivera L, Sáez-Llorens X, Feris-Iglesias J, Ip M, Saha S, Adrian PV, Madhi SA, Boudville IC, Cunnington MC, Casellas JM, Slobod KS. Incidence and serotype distribution of invasive group B streptococcal disease in young infants: a multi-country observational study. BMC Pediatr. 2015 Oct 1;15:143.

 

  1. Pavia-Ruz N, Rossouw M, Sáez-Llorens X, Bunupuradah T, Taylor M, Yang R, Sevinsky H, Krystal M, Lataillade M, Seekins D, Biguenet S. Efavirenz Capsule Sprinkle and Liquid Formulations with Didanosine and Emtricitabine in HIV-1-Infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922. Pediatr Infect Dis J. 2015 Sep 15.

 

  1. Sáez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Han L, Smolenov I, Dull P. Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents. Pediatr Infect Dis J. 2015 Oct;34(10):e264-78.

 

  1. Sáez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, Smolenov I, Dull PM. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents. Hum Vaccin Immunother. 2015;11(6):1507-17.

 

 

  1. Sáez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, Estripeaut D, White K, Arterburn S, Enejosa JV, Cheng AK, Chuck SL, Rhee MS. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. Pediatr Infect Dis J. 2015 Apr;34(4):376-82.

 

  1. Sáez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, Oberste MS, Molina N, Bandyopadhyay AS. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016 Mar;16(3):321-30

 

  1. Asturias EJ, Bandyopadhyay AS, Self S, Rivera L,Saez-Llorens X, Lopez E, Melgar M, Gaensbauer JT, Weldon WC, Oberste MS, Borate BR, Gast C, Clemens R, Orenstein W, O’Ryan G M, Jimeno J, Clemens SA, Ward J, Rüttimann R; Latin American IPV001BMG Study Group. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016 Jul 9;388(10040):158-69

 

  1. Sáez-Llorens X, Tricou V, Yu D, Rivera L, Tuboi S, Garbes P, Borkowski A, Wallace D. Safety and immunogenicity of one versus two doses of Takeda’s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis. 2017 Jun;17(6):615-625

 

  1. Sáez-Llorens X, Rowley S, Wong D, Rodríguez M, Calvo A, Troitiño M, Salas A, Vega V, Castrejón MM, Lommel P, Pascal TG, Hausdorff WP, Borys D, Ruiz-Guiñazú J, Ortega-Barría E, Yarzabal JP, Schuerman L. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial. Hum Vaccin Immunother. 2017 Feb 25:1-16.

 

  1. Sáez-Llorens X, Tricou V, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, Mazara S, Vargas M, Brose M, Rauscher M, Tuboi S, Borkowski A, Wallace D. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis 2018; 18:162-170.

 

  1. Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, Ackerman ME, Arita M, Oberste MS, Weldon WC, Sáez-Llorens X, Bandyopadhyay AS, Wright PF. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J Infect Dis. 2018 Jan 17;217(3):371-380

 

  1. Madhi SA, Rivera LM, Sáez-Llorens X, Menéndez C, Carrim-Ganey N, Cotton MF, Katzman D, Luttig MM, Candelario R, Baker S, Roychoudhury M. Factors influencing access of pregnant women and their infants to their local healthcare system: a prospective, multi-centre, observational study. BMC Pregnancy Childbirth. 2018 Jan 15;18(1):29

 

  1. Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, Mensi I, Keshavan P, Toneatto D. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. Hum Vaccin Immunother 2018 Mar 30:1-14.

 

  1. Ott MA, Crawley FP, Sáez-Llorens X, Owusu-Agyei S, Neubauer D, Dubin G, Poplazarova T, Begg N, Rosenthal SL. Ethical Considerations for the Participation of Children of Minor Parents in Clinical Trials. Paediatr Drugs. 2018 Jun; 20(3):215-222.

 

  1. Caparó Ingram E, Vásquez Vega M, Norero X, Sáez-Llorens X, DeAntonio R, Rodríguez Barría E. Risk factors and lethality associated with neonatal candidemia in a neonatal unit. Rev Chil Pediatr. 2019 Apr; 90(2):186-193.

 

  1. Gaensbauer JT et al. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized with Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame. Clin Infect Dis 2018; 67:S57-S65

 

  1. Biswal S, Reynales H, Sáez-Llorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 2019; 381:2009-2019

 

  1. Biswal S et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomized, placebo-controlled, phase 3 trial. Lancet 2020; 395:1423-1433

 

  1. Tricou V, Sáez-Llorens X, Yu Delia, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomized, placebo-controlled, phase 2 trial. Lancet 2020; 395:1434-1443

 

  1. Sáez-Llorens X, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, in children. Vaccine 2020; 38:3780-3789

 

  1. Cramer J et al. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy children. Vaccine 2020; 38:5313-5323

 

  1. Rivera L, Biswal S, Sáez-Llorens X, et al. Three years efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis. 2021 Oct 4

 

  1. Flores C, Villalobos-Cerrud D, Borace J, Fábrega L, Norero X, Sáez-Llorens X, et al. Epidemiological Aspects of Maternal and Congenital Toxoplasmosis in Panama. 2021 Jun 17;10(6):764.

 

  1. Villarreal A, Rangel G, Zhang X, et al. Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. Front Med (Lausanne) 2021, Mar 2.

 

  1. López-Medina E, Biswal S, Saez-Llorens X, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination. J Infect Dis. 2020, Dec 15

 

  1. Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. 2021 Jan 2;397

 

  1. Bandyopadhyay AS, Gast C, Rivera L, Sáez-Llorens X, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis. 2021 Apr;21(4):559-568.

 

  1. Rivera L, Biswal S, Sáez-Llorens X, et al. Three years efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis. 2021 Oct 4

 

  1. Flores C, Villalobos-Cerrud D, Borace J, Fábrega L, Norero X, Sáez-Llorens X, et al. Epidemiological Aspects of Maternal and Congenital Toxoplasmosis in Panama. 2021 Jun 17;10(6):764.

 

  1. Villarreal A, Rangel G, Zhang X, et al. Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. Front Med (Lausanne) 2021, Mar 2.

 

  1. López-Medina E, Biswal S, Saez-Llorens X, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination. J Infect Dis. 2020, Dec 15

 

  1. Sáez-Llorens X, Bandyopadhyay AS, Gast C, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. 2021 Jan 2;397

 

  1. Bandyopadhyay AS, Gast C, Rivera L, Sáez-Llorens X, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis. 2021 Apr;21(4):559-568.

 

  1. Gast C, Bandyopadhyay AS, Sáez-Llorens X, De Leon T, DeAntonio R, Jimeno J, Aguirre G, McDuffie LM, Coffee E, Mathis DL, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, Fix A, Konz J, Clemens R, Clemens SAC, Rüttimann R.J. Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials. Infect Dis. 2021 Oct 5:507.

 

  1. Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, Yu D, Watanaveeradej V, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Luz K, Venâncio da Cunha R, Rauscher M, Zent O, Liu M, Hoffman E, LeFevre I, Tricou V, Wallace D, Alera MT, Borkowski A; TIDES study group. Three years efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis. 2021 Oct 4:864.

 

  1. Flores C, Villalobos-Cerrud D, Borace J, Fábrega L, Norero X, Sáez-Llorens X, Moreno MT, Restrepo CM, Llanes A, Quijada R M, Ladrón De Guevara M, Guzmán G, de la Guardia V, García A, Lucero MF, Wong D, Mcleod R, Soberon M, Caballero E Z. Epidemiological Aspects of Maternal and Congenital Toxoplasmosis in Panama. 2021 Jun 17;10(6):764.

 

  1. Villarreal A, Rangel G, Zhang X, Wong D, Britton G, Fernandez PL, Pérez A, Oviedo D, Restrepo C, Carreirra MB, Sambrano D, Eskildsen GA, De La Guardia C, Flores-Cuadra J, Carrera JP, Zaldivar Y, Franco D, López-Vergès S, Zhang D, Fan F, Wang B, Sáez-Llorens X, DeAntonio R, Torres-Atencio I, Blanco I, Subía FD, Mudarra L, Benzadon A, Valverde W, López L, Hurtado N, Rivas N, Jurado J, Carvallo A, Rodriguez J, Perez Y, Morris J, Luque O, Cortez D, Ortega-Barria E, Kosagisharaf R, Lleonart R, Li C, Goodridge A. Performance of a Point of Care Test for Detecting IgM and IgG Antibodies Against SARS-CoV-2 and Seroprevalence in Blood Donors and Health Care Workers in Panama. Front Med (Lausanne). 2021 Mar 2; 8:616-106.

 

  1. Sáez-Llorens X, Bandyopadhyay AS, Gast C, Leon T, DeAntonio R, Jimeno J, Caballero MI, Aguirre G, Oberste MS, Weldon WC, Konopka-Anstadt JL, Modlin J, Bachtiar NS, Fix A, Konz J, Clemens R, Costa Clemens SA, Rüttimann. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. 2021 Jan 2;397(10268):27-38.

 

 

  1. Vesikari T, Saez-Llorens X, Blazevic V, Lopez P, Lopez E, Masuda T, Mendelman PM, Liu M, Sherwood J, Baehner F, Borkowski A. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study. 2022 Jun 9;40(26):3588-3596.

 

  1. Wahid R, Mercer L, Gast C, De Leon T, Sáez-Llorens X, Fix A, Macadam A, Stephens L, Chumakov K, Smits SL, Murreddu M, Konopka-Anstadt JL, Steven Oberste M, Burns CC, Andino R, Bachtiar NS, Tritama E, Bandyopadhyay AS, Aguirre G, Rüttimann R, Konz JO. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children. NPJ Vaccines. 2022 Feb 11;7(1):19

 

  1. Tricou V, Gottardo R, Egan MA, Clement F, Leroux-Roels G, Sáez-Llorens X, Borkowski A, Wallace D, Dean HJ. Characterization of the cell-mediated immune response to Takeda’s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting. 2022 Feb 16;40(8):1143-1151

 

  1. Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. HERALD Study Group. Lancet Infect Dis. 2022 Mar;22(3):329-340.

 

  1. López-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, Vargas LM, Alera MT, Velásquez H, Reynales H, Rivera L, Watanaveeradej V, Rodriguez-Arenales EJ, Yu D, Espinoza F, Dietze R, Fernando LK, Wickramasinghe P, Duarte Moreira E, Fernando AD, Gunasekera D, Luz K, da Cunha RV, Tricou V, Rauscher M, Liu M, LeFevre I, Wallace D, Kosalaraksa P, Borkowski A.J. Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. Infect Dis. 2022 May 4;225(9):1521-1532.

 

  1. Díez-Domingo J, Sáez-Llorens X, Rodriguez-Weber MA, Epalza C, Chatterjee A, Chiu CH, Lin CY, Berry AA, Martinón-Torres F, Baquero-Artigao F, Langley JM, Ramos Amador JT, Domachowske JB, Huang LM, Chiu NC, Esposito S, Moris P, Nguyen TL, Nikic V, Woo W, Zhou Y, Dieussaert I, Leach A, Gonzalez Lopez A, Vanhoutte N. Safety and immunogenicity of a ChAd155-vectored RSV vaccine (ChAd155-RSV) in healthy RSV-seropositive children 12-23 months of age. J Infect Dis. 2022 Dec 9:jiac481.

 

  1. Wahid R, Mercer LD, De Leon T, DeAntonio R, Sáez-Llorens X, Macadam A, Chumakov K, Strating J, Koel B, Konopka-Anstadt JL, Oberste MS, Burns CC, Andino R, Tritama E, Bandyopadhyay AS, Aguirre G, Rüttimann R, Gast C, Konz JO. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. Lancet Microbe. 2022 Dec;3(12):e912-e921.

 

  1. Asturias EJ, Bai X, Bettinger JA, Borrow R, Castillo DN, Caugant DA, Chacon GC, Dinleyici EC, Echaniz-Aviles G, Garcia L, Glennie L, Harrison LH, Howie RL, Itsko M, Lucidarme J, Marin JEO, Marjuki H, McNamara LA, Mustapha MM, Robinson JL, Romeu B, Sadarangani M, Sáez-Llorens X, Sáfadi MAP, Stephens DS, Stuart JM, Taha MK, Tsang RSW, Vazquez J, De Wals P. Meningococcal disease in North America: Updates from the Global Meningococcal Initiative.

J Infect. 2022 Dec;85(6):611-622.

 

  1. Sáez-Llorens X, Chan M, DeAntonio R, Petersen T, Olesen C, Jensen JS, Sørensen C, Ekstrand LM, Czort MK, Kristensen HH, Thulstrup N, Christoffersen DB. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. 2022 Sep 22;40(40):5835-5841

 

  1. Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L. Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study. Vaccine X. 2022 Aug;11:100189.